Appachu Sandhya, Obulareddy Chintaparthi, Sirsath Nagesh T, Lakshmaiah Kuntejowdahalli C, Kumari Prasanna
Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Banglore, Karnataka 560029, India.
Ecancermedicalscience. 2013 Aug 15;7:340. doi: 10.3332/ecancer.2013.340. eCollection 2013.
Acute promyelocytic leukaemia (APML) is a biologically and clinically distinct variant of AML, currently classified as acute myeloid leukaemia with recurrent cytogenetic anomalies t(15;17) (q22;q21), promyelocytic leukaemia-retinoic acid receptor alpha, diagnosis regardless of blast count in the World Health Organization classification system. It is one of the curable malignancies, has a unique clinical presentation, often with disseminated intravascular coagulation, and has a targeted therapy for its treatment in the form of all trans retinoic acid (ATRA) and arsenic trioxide (ATO). Here, we report a complex type of variant APML t(3;15) (q26;q13), the need for conventional karyotyping for diagnosing such rare variants, and its response to ATRA and ATO.
急性早幼粒细胞白血病(APML)是急性髓系白血病(AML)在生物学和临床上的一种独特变体,目前在世界卫生组织分类系统中被归类为伴有复发性细胞遗传学异常t(15;17)(q22;q21)、早幼粒细胞白血病 - 维甲酸受体α的急性髓系白血病,诊断时不考虑原始细胞计数。它是可治愈的恶性肿瘤之一,具有独特的临床表现,常伴有弥散性血管内凝血,并且有全反式维甲酸(ATRA)和三氧化二砷(ATO)形式的靶向治疗方法。在此,我们报告了一种复杂类型的变异型APML t(3;15)(q26;q13),诊断此类罕见变异需要进行常规核型分析,以及其对ATRA和ATO的反应。